0000950123-11-061594.txt : 20110624 0000950123-11-061594.hdr.sgml : 20110624 20110624160046 ACCESSION NUMBER: 0000950123-11-061594 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110623 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20110624 DATE AS OF CHANGE: 20110624 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN IDEC INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19311 FILM NUMBER: 11930723 BUSINESS ADDRESS: STREET 1: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 BUSINESS PHONE: 7814642000 MAIL ADDRESS: STREET 1: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 8-K 1 b87116e8vk.htm FORM 8-K e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2011
Biogen Idec Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  0-19311
(Commission
file number) 		  33-0112644
(IRS Employer
Identification No.)
     
133 Boston Post Road, Weston, Massachusetts
(Address of principal executive offices) 		  02493
(Zip Code)
Registrant’s telephone number, including area code (781) 464-2000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     The executive severance arrangement for Francesco Granata, our Executive Vice President of Global Commercial Operations, provides for 21 months of severance benefits if Dr. Granata's employment is terminated because we do not assign him additional global responsibilities and we fail to cure following notice of breach. The date by which we must have assigned him such additional responsibilities has been extended from July 26, 2011 to July 25, 2012. Dr. Granata must notify us that we have breached this obligation no later than January 29, 2013, and we will have 30 days to cure any such breach.

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Biogen Idec Inc.
 		  
  By:   /s/ Robert A. Licht    
    Robert A. Licht   
    Senior Vice President   
 
Date: June 24, 2011